KALA BIO, Inc. develops a dual strategy that combines a clinical-stage biologics pipeline for rare and severe eye diseases with an on-premises artificial intelligence infrastructure platform for biotechnology and pharmaceutical clients. Company updates cover the MSC-S platform, the KPI-012 clinical program, Researgency.ai, and the Bionic Intelligence Research Agent for secure research, clinical, regulatory, and data-workflow applications.
News also addresses capital-structure actions and corporate-status developments, including registered equity offerings, debt settlement, Nasdaq listing matters, governance changes, and the completed 1-for-50 reverse stock split of KALA common stock.
Kala Bio (KALA) and Virotek signed a non-binding letter of intent for a U.S. platform to resell selected Virotek genetic tests.
The September 24, 2026, proposal would add a U.S. DNA testing channel beyond ophthalmology. Kala introduced the potential reseller and would receive a profit split or commission if the deal closes, while Virotek would handle most order-fulfillment logistics. The platform is unnamed, and commercial and economic terms are still being finalized. The companies expect to name the reselling parties in the coming weeks if negotiations are completed.
The letter follows an exclusive U.S. distribution and reseller agreement between Kala and Virotek announced September 3, 2026. Expansion depends on the scope of existing agreements, finalized economic terms, definitive agreements and other customary conditions. The letter is non-binding except for certain limited provisions. Kala has not established a revenue projection.
KALA BIO (KALA) appointed healthcare operator and The LSM Group founder Yenvy Truong to its advisory team to support business growth and acquisition evaluation.
Truong has about two decades of healthcare operations experience, including building and running diagnostic laboratories, and has founded, scaled, and advised companies across genomics, longevity, remote patient monitoring, digital musculoskeletal care, and metabolic medicine. Her work has included mergers, acquisitions, and growth financings totaling more than $200 million in transaction and enterprise value.
KALA is pursuing expansion in diagnostics, genetic testing, and preventive and connected health enhanced by AI, using its existing business, commercial agreements such as its exclusive distribution and reseller agreement with Virotek, new services, and potential acquisitions. Truong serves solely as an advisor, not as an officer or employee.
Kala Bio (KALA) signed a definitive exclusive U.S. distribution and reseller agreement with Virotek for an ophthalmology genomic testing and screening program, effective September 4, 2026, with an initial one-year term and exclusivity tied to commercial milestones.
Under the Agreement, Kala has exclusive rights to market, promote, distribute, and resell Virotek’s ophthalmology genomic program across the United States, while Virotek continues to operate laboratory infrastructure, kit supply, specimen processing, and clinical reporting, and to train Kala’s channel partners. The parties agreed to a profit-sharing structure that begins once Virotek has recovered its program costs, although further commercial terms are not disclosed.
The Agreement also gives Kala a right of first refusal over certain future ophthalmology products and services and establishes a framework to potentially add oncology, preventive-health, telehealth, and white-label distribution verticals by mutual agreement. Kala ties this deal to its staged, capital-efficient partnership strategy and notes that it has not issued any revenue projections and that results are not assured.
Kala Bio (Nasdaq: KALA) and precision health company Virotek signed a non-binding letter of intent outlining principal terms for a definitive agreement that would make Kala the exclusive U.S. distributor and reseller of Virotek’s genetic testing and screening program for ophthalmology.
Under the LOI framework, Kala would market, promote, and distribute the ophthalmology genetic testing program to eye care practices, telehealth platforms, and other U.S. channels, while Virotek would continue to operate the CLIA-registered lab, kit fulfillment, specimen processing, and clinical reporting. The LOI also describes a potential, mutually agreed expansion into other verticals such as oncology, preventive-health testing, and telehealth or white-label channels. The companies are targeting execution of definitive agreements within approximately 30 days, but note there is no assurance that definitive agreements will be reached, as completion remains subject to negotiation, approvals, and customary conditions.
KALA BIO (NASDAQ: KALA) announced a 1-for-50 reverse stock split, effective 4:05 p.m. ET on May 8, 2026. Common stock will trade on a split-adjusted basis beginning at market open on May 11, 2026, under the symbol KALA. The new CUSIP is 483119301.
Outstanding shares will be reduced from 929,491,578 to approximately 18,589,832. Fractional shares will be paid in cash based on the Nasdaq closing price on May 7, 2026. Equity awards, warrants and convertible securities will be proportionally adjusted.
KALA BIO (NASDAQ: KALA) hailed a U.S. Executive Order signed April 18, 2026 that directs FDA priority review of psychedelics, asks DEA to reduce research restrictions, creates expanded Right-to-Try access, and allocates $50 million to accelerate psychedelic therapy research.
KALA says the policy materially strengthens the regulatory and commercial outlook for its client Red Light Holland and increases commercial relevance for KALA’s Researgency.ai agentic AI platform, which Red Light engaged on March 18, 2026.
Kala Bio (NASDAQ: KALA) engaged Dr. Saeid Babaei as Senior Scientific Advisor on April 1, 2026 to evaluate clinical and molecular assets, including its MSC Secretome platform, using AI-enabled analytics, digital health tools, and secure data integration to assess responder hypotheses and amended indication opportunities.
The initial work will review Phase 2 datasets, trial protocols, and translational hypotheses to inform development, partnering, licensing, or commercialization pathways.
KALA BIO (NASDAQ: KALA) announced the commercial launch of the Bionic Intelligence Research Agent (BIRA) on March 30, 2026, delivered via the Researgency.ai platform under an exclusive worldwide license with Younet. BIRA runs a 70-billion-parameter model for biotech and pharma research inside VPN-only, client-controlled infrastructure.
The platform targets enterprise security, audit trails, private data sovereignty, and a platform-as-a-service revenue model, and Kala highlighted a near-term roadmap of four agentic features including alerts, IP monitoring, and compressed publication reviews.
Red Light Holland (CSE: TRIP; FSE: 4YX; OTCQB: TRUFF) engaged Kala Bio's Researgency.ai platform to support clinical development of PEX010, Filament’s patented botanical psilocybin drug candidate. The engagement will deploy agentic AI for clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 following a definitive arrangement to acquire Filament.
PEX010 is supplied to >70 clinical sites, has Health Canada and FDA trial authorizations, and showed positive Phase 2 data in alcohol use disorder; Kala holds exclusive worldwide distribution/development license for Researgency.ai.
Kala Bio (NASDAQ: KALA) rebranded Researgency.ai and says its enterprise AI platform is live, with the company expecting to ship its first commercial AI agent in approximately 14 days. The firm positions Researgency.ai as a secure, auditable OS for biotech agents targeting research, trials, regulatory, safety, and commercial workflows.
Kala frames this move as a shift from a single-drug biotech to a dual-engine company combining an FDA-designated drug pipeline with a scalable AI product aimed at a projected $180+ billion AI-in-healthcare market by 2030.